BioXcel Therapeutics: A Race Against Time

BioXcel Therapeutics finds itself navigating the most severe financial challenge in its corporate history. The biotechnology firm not only reported disappointing third-quarter results but also issued a stark warning about its ability to continue operating. Despite this precarious financial position, the company continues to advance its key clinical programs.

The most alarming development is BioXcel’s recent “going concern” disclosure in its SEC filings. The company has publicly expressed doubt about its capacity to sustain operations over the coming twelve months. This grim assessment stems from persistent financial losses, negative cash flows, limited liquid assets, and troublesome debt conditions.

The third quarter 2025 financial results paint a clear picture of the Read more...